FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523669856> ?p ?o ?g. }

• W2523669856 abstract "Abstract Background: The treatment of patients with chronic lymphocytic leukemia (CLL) with Rituximab in combination with fludarabine and cyclophosphamide was reported to be more efficacious, in terms of complete and molecular remission compared with historical data for fludarabine plus cyclophosphamide (S.O’Brien, Haematologica2002; 87:50–53). Aims: Evaluation of the clinical efficacy and toxicity of the FCR combination in patients of our Haematologic Centre. Methods: Seventeen patients, 8 males and 9 females with a median age of 69,5 years, with relapsed/refractory or de novo CLPD (9 CLL and 8 NHL patients) were enrolled in this study between February 2002 and August 2004. Fifty percent of CLL patients had Rai stage I/II and the rest 50% had Rai stage III/IV disease. Four NHL patients had an International Prognostic Index (IPI) 2, one patient IPI 3 and three patients IPI 4. All patients were treated with Rituximab 375 mg/m2 on day1 in combination with Fludarabine and Cyclophosphamide (25 mg/m2 and 250 mg/m2 respectively) for days 2 to 4, every 4 weeks, for 6 consecutive cycles. Nine patients had a history of a prior unsuccessful treatment. Results: Overall, 14 out of 17 evaluable patients (82%) were responsive to the treatment [12 patients (70%) complete response (CR) and 2 patients (12%) partial response (PR)]. The remaining 3 patients had progressive disease (NR). Hematological toxicity was acceptable (grade 2–3 neutropenia in 6/17 patients, grade 2–3 anemia and thrombocytopenia in 2/17 patients). There were no septic episodes except one case with neutropenic fever. There were no adverse events like nausea or vomiting except one patient with a serious anaphylactic reaction due to Rituximab administration. Three CLL patients died because of progressive disease. Summary/conclusions: this preliminary report suggests that the FCR regimen is an effective and safe treatment for CLPD patients, achieving higher CR rates than previous treatments. A longer follow up of a larger number of patients is required to confirm an improved survival in these patients." @default.
• W2523669856 created "2016-09-30" @default.
• W2523669856 creator A5011887419 @default.
• W2523669856 creator A5014504636 @default.
• W2523669856 creator A5019954410 @default.
• W2523669856 creator A5022859218 @default.
• W2523669856 creator A5042276735 @default.
• W2523669856 creator A5060966245 @default.
• W2523669856 creator A5063008957 @default.
• W2523669856 creator A5069172888 @default.
• W2523669856 creator A5072987204 @default.
• W2523669856 creator A5073659597 @default.
• W2523669856 creator A5084430732 @default.
• W2523669856 date "2005-11-16" @default.
• W2523669856 modified "2023-09-28" @default.
• W2523669856 title "A Phase III Clinical Study of Treatment of Patients with Chronic Lymphoproliferative Disorders (CLPD) with Fludarabine, Cyclophosphamide, and Rituximab (FCR) Combination." @default.
• W2523669856 doi "https://doi.org/10.1182/blood.v106.11.4740.4740" @default.
• W2523669856 hasPublicationYear "2005" @default.
• W2523669856 type Work @default.
• W2523669856 sameAs 2523669856 @default.
• W2523669856 citedByCount "0" @default.
• W2523669856 crossrefType "journal-article" @default.
• W2523669856 hasAuthorship W2523669856A5011887419 @default.
• W2523669856 hasAuthorship W2523669856A5014504636 @default.
• W2523669856 hasAuthorship W2523669856A5019954410 @default.
• W2523669856 hasAuthorship W2523669856A5022859218 @default.
• W2523669856 hasAuthorship W2523669856A5042276735 @default.
• W2523669856 hasAuthorship W2523669856A5060966245 @default.
• W2523669856 hasAuthorship W2523669856A5063008957 @default.
• W2523669856 hasAuthorship W2523669856A5069172888 @default.
• W2523669856 hasAuthorship W2523669856A5072987204 @default.
• W2523669856 hasAuthorship W2523669856A5073659597 @default.
• W2523669856 hasAuthorship W2523669856A5084430732 @default.
• W2523669856 hasConcept C126322002 @default.
• W2523669856 hasConcept C141071460 @default.
• W2523669856 hasConcept C2776694085 @default.
• W2523669856 hasConcept C2776755627 @default.
• W2523669856 hasConcept C2777063308 @default.
• W2523669856 hasConcept C2777938653 @default.
• W2523669856 hasConcept C2778461978 @default.
• W2523669856 hasConcept C2778850193 @default.
• W2523669856 hasConcept C2779263901 @default.
• W2523669856 hasConcept C2779338263 @default.
• W2523669856 hasConcept C2780653079 @default.
• W2523669856 hasConcept C71924100 @default.
• W2523669856 hasConcept C90924648 @default.
• W2523669856 hasConceptScore W2523669856C126322002 @default.
• W2523669856 hasConceptScore W2523669856C141071460 @default.
• W2523669856 hasConceptScore W2523669856C2776694085 @default.
• W2523669856 hasConceptScore W2523669856C2776755627 @default.
• W2523669856 hasConceptScore W2523669856C2777063308 @default.
• W2523669856 hasConceptScore W2523669856C2777938653 @default.
• W2523669856 hasConceptScore W2523669856C2778461978 @default.
• W2523669856 hasConceptScore W2523669856C2778850193 @default.
• W2523669856 hasConceptScore W2523669856C2779263901 @default.
• W2523669856 hasConceptScore W2523669856C2779338263 @default.
• W2523669856 hasConceptScore W2523669856C2780653079 @default.
• W2523669856 hasConceptScore W2523669856C71924100 @default.
• W2523669856 hasConceptScore W2523669856C90924648 @default.
• W2523669856 hasLocation W25236698561 @default.
• W2523669856 hasOpenAccess W2523669856 @default.
• W2523669856 hasPrimaryLocation W25236698561 @default.
• W2523669856 hasRelatedWork W1519967065 @default.
• W2523669856 hasRelatedWork W1925009128 @default.
• W2523669856 hasRelatedWork W2024097666 @default.
• W2523669856 hasRelatedWork W2047361930 @default.
• W2523669856 hasRelatedWork W2100019336 @default.
• W2523669856 hasRelatedWork W2121721101 @default.
• W2523669856 hasRelatedWork W2155033495 @default.
• W2523669856 hasRelatedWork W2162125647 @default.
• W2523669856 hasRelatedWork W2523669856 @default.
• W2523669856 hasRelatedWork W2913496777 @default.
• W2523669856 isParatext "false" @default.
• W2523669856 isRetracted "false" @default.
• W2523669856 magId "2523669856" @default.
• W2523669856 workType "article" @default.